

Mary Gleeson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/916925/publications.pdf>

Version: 2024-02-01

13
papers

442
citations

1306789

7
h-index

1281420

11
g-index

13
all docs

13
docs citations

13
times ranked

1298
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. <i>British Journal of Haematology</i> , 2021, 192, 1015-1019.	1.2	8
2	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. <i>Leukemia and Lymphoma</i> , 2018, 59, 1586-1595.	0.6	10
3	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. <i>Leukemia and Lymphoma</i> , 2017, 58, 1805-1813.	0.6	13
4	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. <i>British Journal of Haematology</i> , 2016, 175, 668-672.	1.2	38
5	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology</i> , 2016, 3, e196-e204.	2.2	344
6	The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial. <i>Blood</i> , 2016, 128, 1746-1746.	0.6	9
7	Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial. <i>Blood</i> , 2016, 128, 1747-1747.	0.6	0
8	Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3215-3216.	0.8	7
9	R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>Blood</i> , 2015, 126, 2689-2689.	0.6	3
10	Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. <i>Blood</i> , 2015, 126, 1499-1499.	0.6	0
11	Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013. <i>Blood</i> , 2014, 124, 1719-1719.	0.6	1
12	Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>Blood</i> , 2014, 124, 1723-1723.	0.6	2
13	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. <i>Blood</i> , 2014, 124, 4417-4417.	0.6	7